Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers

• Status: Recruiting
• Trial end date: 0000-00-00
• Target enrollment: 300
• Participant gender: Female

Summary

The purpose of this study is to compare standard treatment and fusion ontogenetic surgery (total mesometrial resection, laterally extended endopelvic resection, peritoneal mesometrial resection) for gynecologic cancer in order to evaluate treatment response, adverse effect and survival.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Cisplatin; Doxorubicin; Fluorouracil; Liposomal doxorubicin
• Last Updated: 2016-12-06

Criteria

Inclusion Criteria:

• Female, Age ≥ 20 years

• Patients with primary cervical cancer (FIGO stage IB1-IVA)

• Patients with primary uterine cancer (FIGO stage IA, grade 3, IB-IVA)

• Patients who signed an approved informed consent

Exclusion Criteria:

• Female, Age < 20 years

• Patients who refused to sign informed consent